Ari Melnick

Ari Melnick is a leading expert in lymphoma epigenetics whose work on EZH2 mutations and the PRC2 complex has been pivotal in the development of EZH2 inhibitors for lymphoma. He contributed to the preclinical rationale and clinical development of tazemetostat, the first EZH2 inhibitor approved by the FDA. His research identified EZH2 mutations in follicular and diffuse large B-cell lymphoma as oncogenic drivers amenable to targeted therapy. He has led multiple translational research programs linking epigenetic alterations to lymphoma biology and therapy.